Sotorasib is more cost-effective in treating patients with KRAS G12C non–small cell lung cancer (NSCLC) compared with ...
VIENNA -- Using sotorasib (Lumakras) as "lead-in" therapy prior to combining it with immunotherapy was feasible as first-line therapy for patients with advanced KRAS G12C non-small cell lung cancer ...
Sotorasib (Lumakras) was active and well tolerated in patients with metastatic pancreatic cancer with a KRAS G12C mutation, a phase I/II study found. Of 38 patients treated with sotorasib, most of ...
French investigators are warning clinicians who treat patients with non–small cell lung cancer (NSCLC) not to initiate treatment with sotorasib within 30 days of an immunotherapy infusion with an anti ...
The KRAS mutation occurs in 13% of non–small cell lung cancers (NSCLC) and leads to worse outcomes in NSCLC. The findings about the oral agent were published simultaneously in the New England Journal ...
Sotorasib conferred durable clinical benefit among previously treated patients with KRAS p.G12C-mutated non-small cell lung cancer, according to results of the phase 2 CodeBreaK 100 trial presented ...
Last year Amgen intrigued scientists and investors alike after announcing data showing it had produced the first drug that seemed to work against KRAS mutations, which are found in lung and other ...
Please provide your email address to receive an email when new articles are posted on . The ongoing, single-arm CodeBreak 100 trial included 62 patients with KRAS G12C-mutated colorectal cancer across ...
Participants with advance non-small cell lung cancer and colorectal cancer experienced the greatest benefits in this first-in-human phase 1 clinical trial. DUARTE, Calif.--(BUSINESS WIRE)--A phase 1 ...
A phase 1 clinical trial of sotorasib (AMG 510) in patients with heavily pretreated advanced solid tumors shows encouraging anti-cancer activity, especially in lung and colorectal cancers, reports a ...
NICE has recommended sotorasib for use within the Cancer Drugs Fund as an option for treating KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults ...
KRAS, one of the most frequently mutated oncogenes in human cancer, has long been thought to be "undruggable," but early results from a clinical trial of the experimental KRAS-inhibitor sotorasib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback